SARS‑CoV‑2 Antibodies (IgG Nucleocapsid, IgM Spike), Qualitative
Also known as: Novel Coronavirus, Wuhan, COVID19, nCOV, Coronavirus
Use
Intended for qualitative detection of both IgG antibodies targeting SARS‑CoV‑2 nucleocapsid and IgM antibodies targeting SARS‑CoV‑2 spike in human serum or plasma, as an aid in identifying recent or prior infection and adaptive immune response to SARS‑CoV‑2. Not for diagnosing or excluding acute infection; the clinical significance of antibodies (especially post‑vaccination) and their persistence are not well characterized and may not indicate protective immunity. ([questdiagnostics.com](https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq219?utm_source=openai))
Special Instructions
Not provided.
Limitations
Not intended for diagnosis of acute SARS‑CoV‑2 infection. Timing of antibody response varies; false negatives can occur early post-infection. The duration of detectability of IgG and IgM antibodies post-infection is not well defined, and presence of antibodies does not guarantee immunity. Cross-reactivity or background reactivity may occur; results must be interpreted with clinical context and other testing. Performance characteristics post-vaccination are not established. ([questdiagnostics.com](https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq219?utm_source=openai))
FDA Approved
Methodology
Immunoassay
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
Not provided
Other tests from different labs that may be relevant